Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results [Financial Post (Toronto, Ontario, Canada)]
Elevai Labs, Inc. (ELAB)
Company Research
Source: Financial Post
Company reports record annual revenues of $1.71 Million for 2023, up 123.5% over the previous year Company reports record Q4 2023 revenues of $698,591, up 403% from Q4 2022 Article content NEWPORT BEACH, Calif., March 29, 2024 (GLOBE NEWSWIRE) — Elevai Labs Inc. (NASDAQ: ELAB), a medical aesthetic company specializing in physician-dispensed skincare, today reported financial results for the fourth quarter and full year ended December, 31, 2023. “This year has been pivotal for us, with our revenue more than doubling, it's a clear indicator of our market strength and customer trust,” stated Elevai Labs CEO, Jordan R. Plews, PhD. “We are proud to have increased our operating, production and supply chain efficiency as evidenced in the improvement of our gross margin and are excited to further advancements at the interface between aesthetics and biotechnology. This marks just the beginning of our ambitious vision for the future.” Article content Financial Results for the Three
Show less
Read more
Impact Snapshot
Event Time:
ELAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELAB alerts
High impacting Elevai Labs, Inc. news events
Weekly update
A roundup of the hottest topics
ELAB
News
- Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity [Yahoo! Finance]Yahoo! Finance
- Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of ObesityGlobeNewswire
- Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare [Yahoo! Finance]Yahoo! Finance
- Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome SkincareGlobeNewswire
ELAB
Sec Filings
- 5/9/24 - Form 8-K
- 5/2/24 - Form 8-K
- 3/29/24 - Form 10-K
- ELAB's page on the SEC website